Loading provider…
Loading provider…
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician in Philadelphia, PA
NPI: 1174758791Primary Practice Location
HOSPITAL OF UNIV OF PENNSYLVANIA
3400 Spruce St, Philadelphia, PA
Primary Employer
Perelman Center for Advanced Medicine
pennmedicine.org
HQ Phone
Get MD Nirali's Phone Numberphone_androidMobile
Get MD Nirali's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License
PA State Medical License

American Board of Ophthalmology
Ophthalmology
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 34 | 48 |
The Rate of Failure of Trabeculectomy and Tube Shunt Surgery in Eyes with Uveitic Glaucoma and Ocular Hypertension.
Authors: Sylvia Groth, Craig Newcomb, Wei Yang, Abhishek Payal, Hosne Begum, Naira Khachatryan, R Kaçmaz, Kurt Dreger, James Rosenbaum, H Sen, Eric Suhler, Jennifer Thorne, Nirali Bhatt, C Foster, Douglas Jabs, Grace Levy Clarke, Jeanine Buchanich, Gui-shuang Ying, John Kempen, Sapna Gangaputra
Publication Date: 2025-03-27
Contemporaneous Risk Factors for Visual Acuity in Non-Infectious Uveitis.
Authors: James Rosenbaum, Grace Levy-Clarke, Jennifer Thorne, Eric Suhler, Sapna Gangaputra
Journal: Ocul Immunol Inflamm
Publication Date: 2021-02-23
Lead Sponsor: JHSPH Center for Clinical Trials
Intervention / Treatment: BIOLOGICAL: Adalimumab (ADA), DRUG: Conventional immunosuppression (CON)
Lead Sponsor: JHSPH Center for Clinical Trials
Collaborators: National Eye Institute (NEI)
Intervention / Treatment: DRUG: Dexamethasone intravitreal implant 0.7 mg, DRUG: Intravitreal Methotrexate 400 µg, DRUG: Intravitreal Ranibizumab 0.5 mg
Lead Sponsor: JHSPH Center for Clinical Trials
Collaborators: National Eye Institute (NEI)
Intervention / Treatment: DRUG: Periocular triamcinolone 40 mg, DRUG: Intravitreal triamcinolone 4 mg, DRUG: Dexamethasone intravitreal implant